NRx Pharmaceuticals has received a first safety report from a Southwestern hospital where physicians have administered ZYESAMI® (Aviptadil) to patients with COVID-19 respiratory failure.
RIght to Try
Jan. 26, 2022NRx Receives Initial Report of Patient Safety and Survival from Right to Try use of ZYESAMI® (aviptadil) during Omicron Surge
Aug. 31, 2021CEO Update: Right to Try
A year ago, at FDA’s request, NRx began a compassionate care (Expanded Access) program to make aviptadil more available to patients in need. We have reported our experience in nearly 350 patients, and numerous patients and families have shared their stories in various public forums. The compassionate care program was, of necessity, limited to a […]